Providence cancer researchers make national headlines
Eric Tran, Ph.D.
Rom Leidner, M.D.
Providence Cancer Institute is among a handful of centers in the world capable of developing a type of cancer immunotherapy called adoptive cell therapy.
Under the leadership of Eric Tran, Ph.D., and Rom Leidner, M.D., our team has pioneered a second-generation adoptive cell therapy using genetically engineered T cells, a type of immune cell capable of destroying cancer cells.
Their innovative work is published in the New England Journal of Medicine article Neoantigen T-Cell Receptor-Gene Therapy in Pancreatic Cancer available in the June
2, 2022, issue.
- New England Journal of Medicine article
- Providence blog post
- NY Times
- Associated Press
- NBC News (web story)
- Portland Business Journal
Philanthropy funds more than 70% of our cancer research. This work would not be possible without the generous support of donors and the participation of patients whom we are privileged to serve. Thank you.
Interested in learning more about available clinical trials? Please contact CanRsrchStudies@providence.org or call 503-215-1979.